HANDOK Inc. (002390.KS)

KRW 11580.0

(-1.03%)

Market Cap (In KRW)

159.38 Billion

Revenue (In KRW)

522.74 Billion

Net Income (In KRW)

-28.79 Billion

Avg. Volume

16.5 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11100.0-20300.0
PE
-
EPS
-
Beta Value
0.587
ISIN
KR7002390003
CUSIP
-
CIK
-
Shares
13763500.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Young-Jin Kim M.B.A.
Employee Count
-
Website
https://www.handok.co.kr
Ipo Date
2000-01-04
Details
Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.

More Stocks